Our areas of research
Our areas of research
Janssen helps to shape the research landscape by investing in outstanding research competencies in the areas of genome science, biotechnology, biomarkers, personalised diagnosis and vaccine platforms. We have early stage access to groundbreaking innovations in all hotspots across the globe. We embrace the most promising science and encourage collaboration in order to be able to discover and continually develop better, more advanced medication.
Focus on complex medical challenges
Our efforts are mainly focused on a number of the most distressing disorders and most complex medical challenges of our time. To achieve this we bring together top scientists and researchers in our six therapeutic domains.
Neurosciences deal with various psychiatric and neurological disorders such as psychoses, mood disorders, dementia, pain, schizophrenia and Alzheimer’s disease. A tradition of research dating back more than 60 years and a range of successful drugs have made Janssen a leading authority in this domain. Nevertheless, medical needs continue to dominate not least because of rapidly ageing.
Oncology deals with everything related to research into and treatment of cancer. Cancer occurs in many different forms and types, which means that there is no single solution or treatment available. Janssen specializes in the treatment of breast cancer, lung cancer, prostate cancer, blood cancers and bowel cancer. Our ultimate goal is to make cancer a preventable, chronic or eventually curable disease.
Infectious Diseases & Vaccines
An infectious disease is caused by the presence of one or more microbial agents (microorganisms) such as a bacterium, virus, mould or abnormal protein. Despite progress made in the field of infectious diseases, these disorders still have a major impact on the health of many people across the world. We would like to offer innovative solutions for the prevention and treatment of disorders such as flu RSV (respiratory syncytial virus), hepatitis, HIV/aids, tuberculosis and other infectious diseases.
We have a rich history in the development of medicines to combat immunological disorders. Immunology is the branch of science that focuses on research into the immune system. We continue to augment our expertise through expansion of our pipeline of innovative products for the treatment of complex immunological diseases such as rheumatoid arthritis,IBS ('irritable bowel syndrome'), ulcerative colitis and psoriasis.
Cardiovascular & Metabolic Diseases
Cardiovascular diseases, diabetes and obesity are a growing medical challenge in the 21st century that are aggravated by poor eating habits and an unhealthy lifestyle. Expenditure on, for example, cardiovascular disease is costing the EU 192 billion euro per annum. Janssen also focuses on this specific research field in order to offer innovative solutions to people suffering from such diseases.
In June 2017, Actelion became part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
Actelion, headquartered in Allschwil, a town on the western suburb of Basel, Switzerland, is an industry leader in the field of pulmonary hypertension (PH), and most notably, pulmonary arterial hypertension (PAH). Its portfolio of PAH treatments covers the spectrum of disease, from WHO Functional Class (FC) II to IV, with oral, inhaled and intravenous medications.
Over the past two decades, Actelion's medicines have helped to significantly improve the prognosis and quality of life for people affected by PH.
Janssen has added PH as a therapy area of focus, to maintain and expand Actelion’s leadership position.
To learn more about PH, Actelion and its medicines, please visit www.actelion.com or follow @actelion_com.